1 Biofabrication of multiplexed electrochemical immunosensors for

2 simultaneous detection of clinical biomarkers in complex fluids

- 4 Ingber^{1,4,5,*}
- ¹Wyss Institute for Biologically Inspired Engineering, Harvard University, 02115, USA,
- 6 ²Department of Bioengineering, University of Texas at Dallas, Texas, 75080, USA,
- ³Department of Biomedical Engineering, University of Cincinnati, Ohio, 45220, USA,
- 8 ⁴Vascular Biology Program, Boston Children's Hospital, and Harvard Medical School, 02115, USA and
- 9 ⁵Harvard John A. Paulson School of Engineering and Applied Sciences, Harvard University, 02115, USA
- 10 ⁺Current address: *StataDX Inc., Boston, MA 02215, USA*
- 11
- 12 *Address all correspondence to: Donald E. Ingber, MD, PhD., Wyss Institute at Harvard University,
- 13 CLSB5, 3 Blackfan Circle, Boston MA 02115 (ph: 617-432-7044, fax: 617-432-7828; email:
- 14 don.ingber@wyss.harvard.edu
- 15

16 Abstract

17 Simultaneous detection of multiple disease biomarkers in unprocessed whole blood is 18 considered the gold standard for accurate clinical diagnosis. Here, we report the development of a 19 4-plex electrochemical (EC) immunosensor with on-chip negative control capable of detecting a 20 range of biomarkers in small volumes (15 µL) of complex biological fluids, including serum, 21 plasma, and whole blood. A framework for fabricating and optimizing multiplexed sandwich 22 immunoassays is presented that is enabled by use of EC sensor chips coated with an ultra-selective, 23 antifouling, nanocomposite coating. Cyclic voltammetry evaluation of sensor performance was 24 carried out by monitoring the local precipitation of an electroactive product generated by 25 horseradish peroxidase linked to a secondary antibody. EC immunosensors demonstrated high 26 sensitivity and specificity without background signal with a limit of detection in single-digit pg/mL 27 in multiple complex biological fluids. These multiplexed immunosensors enabled simultaneous 28 detect of four different biomarkers in plasma and whole blood with excellent sensitivity and

³ Sanjay S. Timilsina^{1,+}, Mohanraj Ramasamy^{1,2,3}, Nolan Durr¹, Rushdy Ahmad¹, Pawan Jolly¹, Donald E.

selectivity. This rapid and cost-effective biosensor platform can be further adapted for use with
 different high affinity probes for any biomarker, and thereby create for a new class of highly

3 sensitive and specific multiplexed diagnostics.

4

5 Key Words: Electrochemical Biosensor, Fabrication, Surface Chemistry, Hematocrit, Multiplexing,

6

7 1. Introduction

8 The ongoing paradigm shift from reactive healthcare to preventive health care has increased 9 interest in patient-centric diagnostic devices that could be used in everyday life. Direct detection of 10 relevant disease biomarkers in whole blood could circumvent expensive and time-consuming sample 11 preparation procedures that are currently required in clinical laboratories so that diagnotic assays could be performed in point-of-care (POC) settings, including physicians offices, pharmacies, and even at home.^[1] 12 13 Widely used detection techniques like optical detection cannot be used for whole blood detection because 14 of strong scattering, absorption, and considerable autofluorescence in these complex biological samples.^[2] 15 Complex biological fluids, such as whole blood, plasma, and serum are also difficult to analyze due to 16 high concentrations of sticky proteins and other molecules that can reduce signal detection and increase 17 background noise. While some of these negative effects can sometimes be partly reduced by sample 18 dilution, many biomarkers are present near the assay's detection limit, and the dilution of samples is not 19 always linear.^[3] 20 One potential way to overcome these diagnostic challenges is through the use of electrochemical 21 (EC) sensors that can provide rapid, accurate, and quantitative detection of disease biomarkers in complex

fluids.^[4] Because they generate an electrical signal as an output, they also can seamlessly integrate with

23 wireless data collection and transmission systems. But while significant basic research has been

24 conducted on developing multiplexed EC POC devices for disease diagnosis, very few products have

25 been translated to the clinical setting.^[5] There are various reasons for this, including biofouling of

electrodes by components with complex biological fluids (sweat, saliva, blood, plasma), the complexity

of building bioassays on the electrodes, challenges related to development of multiplexing capabilities,

28 sensitivity to changes in environmental cues, and the need to develop sophisticated readouts and

analytical tools for analysis of complex data generated with these types of devices.^[6]

We have recently developed an engineering solution to address these challenges and create a
 clinically translatable EC platform for rapid detection and quantification of clinically relevant disease
 biomarkers in small volumes of complex biological fluids, including whole human blood. Key to this

advance was the development of a novel antifouling electroconductive nanocomposite coating to combat
EC biosensors, which enabled engineering of an EC sensor platform that provides effective and accurate
detection of several biomarkers that may be used for diagnosis of various diseases with clinical
significance.^[5, 7] The coating method involves brief (1 minute), localized, heat-induced coating of EC
sensors with a nanocomposite composed of denatured bovine serum albumin cross-linked with
pentaamine functionalized graphene oxide cross-linked with glutaraldehyde (BSA/prGOx/GA).^[8]


7 Multiplexing is a critical requirement for POC devices because disease and pathophysiology often 8 involves interplay among many complex biological processes, and hence accurate diagnosis requires detection of several molecules rather than a single biomarker entity.^[4c, 9] Establishment of a multiplexed 9 detection platform therefore makes it possible to stratify and monitor complex multifactorial diseases with 10 high confidence in conjunction with relevant validated biomarkers.^[10] In addition, multiplexing minimizes 11 assay costs, time, and sample volume while concurrently enabling efficient monitoring and prediction of 12 disease progression and outcome.^[11] To develop this type of multiplexed platform, it is imperative to 13 14 immobilize optimized concentrations of high affinity bioreceptor molecules for the target of interest on 15 the electrode surface, which in combination with a specific detection antibody provides a high level of 16 signal sensitivity. The coating density of bioreceptors on the electrode surface is critical in achieving the 17 optimal surface-to-volume ratio necessary for the efficient capture and detection of the biomarker in the test sample.^[12] 18


19 Here, we describe methods and tools that can be used to biofunctionalize nanocomposite coated 20 multi-electrode sensor chips and to assess sensor functionality to detect multiple analytes in the presence 21 of complex biological fluids. A sandwich enzyme-linked immunosorbent assay (ELISA) is employed for 22 signal detection that uses secondary antibodies linked to horseradish peroxidase (HRP) enzyme, which 23 generate an electroactive, insoluble, 3,3,5,5-Tetramethylbenzidine (TMB) product that precipitates locally 24 at the molecular binding site above the electrode surface, and thereby enables a multiplexing capability. 25 Different assay parameters were optimized to create an immunoassay with optimum probe density and 26 TMB precipitation to develop a multiplexed assay with required sensitivity and specificity without 27 electrochemical background signal. Using this approach, an immunoassay with single-digit pg/mL 28 sensitivity was developed that was not influenced by clinically relevant hematocrit levels in whole blood, 29 which can potentially be translated into development of diagnostics for POC settings. We describe how 30 we used framework for sensor assay development to create optimized EC sensors that enable multiplexed 31 detection of a range of protein biomarkers for multiple clinically relevant conditions and disease, 32 including sepsis, active pulmonary tuberculosis (TB), myocardial infarction (MI), traumatic brain injury (TBI), and multiple sclerosis (MS). 33

1 2. Results

2 2.1 Fabrication of electrochemical biosensors

3 The methods used for fabrication of our EC sensors are critical for their high functionality. Clean 4 gold sensor electrodes were first treated with plasma cleaner for 8 min (Figure S1, Supporting Information) and modified with bioinspired nanocomposite coating composed of glutaraldehyde (GA) 5 6 cross-linked with denatured bovine serum albumin (BSA) intercalated with pentaamine modified reduced graphene nanoparticles (prGOx) via rapid coating method as described previously^[8a] prior to 7 8 immobilizing antibodies (Figure 1). Importantly, we also found that this antifouling coating application 9 method can also be applied to other relevant electrode materials, such as a gold electroplated printed 10 circuit board (PCB) on polyethylene terephthalate (PET) substrate from Linxens and a 3D graphene foambased sensing electrode (Gii-Sens, from Integrated Graphene). Cyclic voltammetry (CV) analysis of the 11 12 coated Linxens sensors confirmed that they maintain similar currents as the bare electrode (Figure S2, Supporting Information). On the other hand, a slight decrease in the peak current was observed after 13 14 coating the Gii-sens electrodes, which could be attributed to the porous structure of graphene foam, which 15 was filled after applying the coating (Figure S3a, Supporting Information). 16 The coating on these sensors was then activated with 1-ethyl-3-[3-dimethylami- nopropyl]-17 carbodiimide hydrochloride/ N-hydroxysuccinimide (EDC/NHS) and incubated with bioreceptor 18 molecules (i.e., capture antibodies), resulting in the formation of covalent links between free carboxylate 19 groups of the coating and primary amines of the antibody; unreacted carboxylate groups were 20 subsequently quenched with ethanolamine (Figure 1b). Although there was a slight decrease in the 21 current with coated Gii-sens electrodes, functionalization of the coated electrode directly with HRP 22 enzyme (as a positive control) only showed a high signal when its TMB substrate was added with no 23 signal in negative control (Figure S3b, Supporting Information). Thus, these findings indicate that the 24 antifouling nanocomposite coating can be applied to various kinds of sensors and support selective 25 binding of desired capture molecules on top of the electrode surface.





9

1


10 Coated immunosensors with immobilized capture antibodies were then exposed to samples 11 containing the antigen and a secondary biotinylated detection antibody. Upon incubation, the specific 12 antigen is sandwiched between the capture and biotinylated detection antibodies (Figure 1c). Next, the 13 sensors are washed and exposed to streptavidin poly-horseradish peroxidase (spHRP), which binds to the 14 biotinylated detection antibody (Figure 1d). Finally, the TMB substrate for the HRP enzyme is added, 15 which results in production of an insoluble electroconductive product that locally precipitates at the reaction site and is electrochemically read using cyclic voltammetry (Figure 1e). Typical CVs are 16 17 obtained with the immunosensor, where the peak height is directly proportional to the amount of target detected (Figure 1f). 18

- 20 2.2 Electrochemical immunoassay development
- 21 The nanocomposite-coated EC sensors can be used to develop both two-step (incubation of
- sample followed by washing and addition of detection antibody) and single-step (incubation with

pre-mixed sample and detection antibody) assays; however, their effectiveness requires 1 optimization of critical reagents and processes that are used to define assay performance. Using 2 3 the nanocomposite coating, we found that the highest sensitivity and specificity were achieved 4 by optimizing the concentration of capture and detection antibody, spHRP, as well as the TMB incubation time. Initially, a two-step assay was evaluated using the MI biomarkers, cardiac 5 troponin I (cTnI) and N-terminal (NT)-pro hormone BNP (NT-proBNP), as targets. These 6 biomarkers show variable levels in circulation according to the clinical condition and timing of 7 measurement and thus require a rapid and sensitive POC device for clinical use.^[13] Plasma 8 samples were added to the EC sensor followed by an optimized concentration of 1 µg/mL 9 detection antibody to achieve a sensitivity of 24 and 3 pg/mL for cTnI and NT-proBNP, 10 respectively, with assay times of 1 h and 21 min (Figure S4, Supporting Information). The EC 11 12 sensor also was not able to achieve the clinical threshold for cTnI, which is 16 pg/ml in female.^[13b] 13

14

Assay development was then carried out to develop a rapid biosensor with decreased assay time 15 16 while maintaining high sensitivity and specificity for single-step detection of the different biomarkers. Surface coverage plays a critical role in defining the performance of the EC sensor 17 18 and can be optimized to reduce steric hindrance for efficient binding. Different concentrations of anti-cTnI capture antibody (50 µg/mL-1000 µg/mL) were evaluated to detect high, low and zero 19 20 concentrations of the analyte (10, 0.1, and 0 ng/mL, respectively). The electrical signal generated with the 10 ng/mL analyte increased as the concentration of the capture antibody was raised from 21 22 50 to 500 µg/mL as expected but it decreased when the antibody concentration was further raised from 500 to 1000 µg/mL, which may be due to surface crowding (Figure 2a).^[14] 500 µg/mL of 23 24 capture antibody also resulted in the highest signal-to-noise ratio, and a significant difference 25 between lowest concentration and blank. This 500 µg/mL capture antibody concentration was then used to optimize the detection antibody concentration in the range of $1-8 \mu g/mL$ with high, 26 low, and blank analyte. 27



1

2 Figure 2: Optimization of assay condition for detection of cTnI in EC biosensor. a) Optimization of cTnI 3 capture antibody. Bar graph shows the mean current density for different concentration of capture 4 antibody (50, 100, 500, and 1000 µg/mL) to perform assay of cTnI at 3 different concentrations (10, 0.1, 5 and 0 ng/mL). b) Optimization of cTnI detection antibody. Bar graph shows the mean current density for 6 different concentration of detection antibody (1, 2, 3, 5, and 8 μ g/mL) to perform assay of cTnI at 3 7 different concentrations (10, 0.1, and 0 ng/mL). c) Optimization of Streptavidin-poly-HRP (spHRP). Bar 8 graph shows the mean current density for different concentration of spHRP (1, 2, 3, 5, and 8 ug/mL) to 9 perform assay of cTnI at 3 different concentrations (10, 0.1, and 0 ng/mL). d) Optimization of TMB 10 incubation time. Bar graph shows the mean current density for different incubation time for TMB (1 and 11 2 min) to perform assay of cTnI at different concentrations (10, 1, 0.5, 0.1, 0.05, 0.01, and 0 ng/mL). Error bars represent the s.d. of the mean; n=3. Significant difference was determined by unpaired two-12 tailed t-test (ns P > 0.05; *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001). 13 14

- 15 Using this optimized biosensor, we found that the signal for 10 ng/mL analyte increased when
- 16 the concentration of anti-cTnI detection antibody was raised from 1 to $2 \mu g/mL$, the signal then
- plateaued from when the concentration was further increased from 2 to 5 μ g/mL, and it finally
- declined from 5 to 8 μ g/mL (**Figure 2b**), which could be due to over precipitation of TMB

making the surface less conductive. A signal for lower concentration (0.1 ng/mL) of analyte was
seen only for detection antibody concentrations of 5 µg/mL and above, while 8 µg/mL of
detection antibody resulted in non-specific binding similar to that observed for the blank.

4

We then used 5 μ g/mL of detection antibody that had the highest signal-to-noise ratio to further 5 optimize spHRP. Using 10 ng/mL of analyte, we found the signal generated to be consistent 6 when we added 1 to $5 \mu g/mL$ spHRP, but with higher concentrations, there was over 7 8 precipitation of substrate leading to a decrease in signal (Figure 2c). Lowest concentration (0.1 9 ng/mL), started showing signal when concentration of spHRP was $3 \mu g/mL$ or higher with no significant difference between lowest concentration and blank at 3 µg/mL of spHRP. At 5 µg/mL 10 of spHRP, there was a significant difference between 0.1 ng/ml and blank. However, a high non-11 12 specific signal was observed at 8 μ g/mL spHRP. Thus, we viewed 5 μ g/mL spHRP to be the optimal concentration for use in these studies. 13

14

15 Finally, all the optimized conditions were used to evaluate the TMB precipitation time.

16 Calibration curves were run from 0.01 to 10 ng/mL with a TMB precipitation time of 1 versus 2

17 min. With the 1 min precipitation time, no signal was observed for lower TMB concentrations

18 (0.05 and 0.01 ng/mL); however, signals were observed over the whole calibration range with

19 the 2 min precipitation (Figure 2d). Longer precipitation times led to a non-specific signal, so

20 the 2 min TMB precipitation time was considered optimum for the assay.

21

The coating time of the sensor with antifouling nanocomposite was also assessed by performing 22 23 the EC sandwich assay for detection of 4 different concentrations (1, 0.1, 0.05, and 0 ng/mL) of 24 cardiac troponin complex (cTnITC). We found that there was no significant difference at higher 25 concentrations, but the 45 sec coating time gave the highest signal-to-noise ratio at lower analyte concentration (0.05 ng/mL) (Figure S5a; Supporting Information), and thus coating time of 45 26 27 sec was used for all susequent studies. Interestingly, we found that this 45 sec rapid coating procedure resulted in production of bioassays that were as sensitive as those previously created 28 using a 24 h coating^[8b], as demonstrated by the absence of any significant difference in the signal 29 generated in the cTnITC assay at lower analyte concentrations (Figure S5b, Supporting 30 Information). In addition, the biosensors can be stored at room temperature for at least a week 31

after the completion of the assay^[8a] and still generate a similar signal. For example, when we ran
a full calibration curve (0.01 to 10 ng/mL cTnITC) there was no significant difference between
the signal read out immediately after sensor fabrication or after incubating in the dark for 24 h
(Figure S5c, Supporting Information).

5

As the ultimate aim was to perform a multiplexed assay with the same reagents, the spHRP 6 concentration and TMB precipitation time were kept constant, and only the detection antibody 7 8 concentration was optimized for the other biomarkers. Similar to optimization of the anti-cTnI 9 detection antibody, we found that $9 \mu g/mL$ of anti-BNP detection antibody and $6 \mu g/mL$ of anti-NT-proBNP and anti-cTnITC complex detection antibodies gave the highest signal-to-noise 10 ratios (Figure S6a-c, Supporting Information). Furthermore, similar to the biomarkers for MI, 11 12 we also optimized capture and detection antibody concentration for previous described biomarkers for active pulmonary TB.^[15]. We found that 1 mg/mL was the optimal capture 13 antibody concentration for interleukin-6 (IL-6), IL-8, IL-18, and vascular endothelial growth 14 factor (VEGF) using an optimal concentration of detection antibody of 2 µg/mL (Figure S7.8, 15 16 Supporting Information).

17

18 2.2 EC biosensor analytical performance

To explore the potential value of this approach for clinical diagnostics, we leveraged these 19 biomarkers to construct a prototype POC affinity-based ELISA on miniaturized electrodes, 20 21 which could be used to develop a low-cost, rapid, ultra-low volume, and easily accessible bloodbased triage test for TB. We performed sandwich ELISA on the EC biosensor containing the 22 23 immobilized capture antibodies for the TB biomarkers described above and carried out calibration curves covering their clinical ranges (Figure 3). We obtained a limit of detection 24 25 (LOD) of 1000, 3, 9, 5, and 17 pg/mL for Ag85-B, IL-6, IL-8, IL-18, and VEGF, respectively. Importantly, the LODs for all of the TB biomarkers were better than the clinical cut-off values 26 (Table 1, Supporting Information).^[15-16] 27


28


29 To explore the generality of this approach, we carried out a similar EC sandwich assay using

30 specific capture antibodies for procalcitonin (PCT), a 116-amino acid peptide precursor for

31 calcitonin which has a strong association with hepatitis C virus (HCV), sepsis, and other

bacterial infections. We obtained LOD of 4 pg/mL, which is also more sensitive than the clinical
cut-off value (**Table 1**, Supporting Information).^[10, 17] In addition, we performed a neurofilament
light polypeptide (NF-L) assay using unprocessed whole blood on the Linxens sensor. NF-L is
considered a promising biomarker for MS that has been shown to reflect disease activity in the
clinical follow-up of the MS patients.^[18] With the Linxens sensor, a LOD of 0.3 pg/mL was
obtained for NF-L using whole blood, which can be attributed to the highly efficient antifouling
capability of our nanocomposite coating (**Figure S9**, Supporting Information).





10 Biosensors. The left y-axis shows the current intensity for different concentrations of biomarkers run on

1 EC biosensors using unprocessed human plasma. Different biomarkers tested include a) IL-6, b) IL-8, c)

IL-8, d) VEGF, e) Ag85B, and f) PCT. Error bars represent the s.d. of the mean; n = 3. Analysis was done using 4-Parameter Logistic (4PL) curve fitting.

4

5 2.3 Cross-reactivity of Antibody pair and Antigen

6 Cross-reactivity can be a significant issue in diagnostic immunoassays as it can result in over-or

7 underestimation of sample analyte concentration.^[19] Thus, we performed a detailed cross-

8 reactivity study for different pairs of MI and TBI antibodies and antigens, including NT-proBNP,

9 in conventional plastic ELISA plates (Figure 4a). Using an anti-NT-proBNP capture antibody

10 with 10 ng/mL of the NT-proBNP analyte, we found that addition of multiple different

11 secondary detection antibodies, including those directed against cTnI, BNP, S100, and glial

12 fibrillary acidic protein (GFAP), failed to generate any detectable single compared to the blank,

13 confirming that there is no non-specific binding of detection antibodies or cross-reactivity in this

14 assay.

15

16 We also explored whether the NT-proBNP analyte binds non-specifically to other capture

17 antibodies (anti-cTnI, anti-BNP, anti-S100, and anti-GFAP) by coating ELISA plates with

18 different capture antibodies followed by the addition of 10 ng/mL NT-proBNP and anti-NT-

19 proBNP detection antibody. A minimum signal similar to blank was observed in each case

20 (Figure 4a), again showing no cross-reactivity. Likewise, cross-reactivity of antibody pairs and

antigens were also performed for BNP, GFAP, and S100 with all other capture and detection

22 antibodies (**Figure 4b,c,d**). Concentration-based signals were observed only for specific

antibody pairs, and no signal was observed using non-specific antibodies or target analytes; thus,

these antibody pairs (NT-proBNP, BNP, GFAP, and s100) can be used for multiplexed detection

in single assay.

26

For Troponin I, two antibody pairs (anti-cTnI and anti-cTnI-TC) were tested for cross-reactivity
with other antibody pairs (BNP, NT-proBNP, GFAP, and s100) along with specific analytes,
cTnI and cTnITC complex. We were able to demonstrate specific detection of cTnITC with an
anti-cTnI antibody pair, which produced a lower specific signal and higher non-specific binding
with BNP and a NT-proBNP capture antibody(Figure S10a; Supporting Information). We also
obtained a concentration-dependent signal for cTnI with using anti-cTnI antibody pair, but

observed very high non-specific binding of cTnI to BNP and NT-proBNP capture antibodies 1 (Figure S10b; Supporting Information). Similar high specific signals were obtained for cTnITC 2 3 using anti-cTnI-TC antibody pair, while there was almost no signal with the non-specific antibody pair (Figure S10c; Supporting Information). There was also very low specific binding 4 of the anti-cTnI-TC antibody pair for cTnI (Figure S10d; Supporting Information). Thus, we can 5 use the anti-cTnI-TC antibody pair (Figure S10c) with high specific signal for cTnITC and 6 minimum cross-reactivity to other antibody pairs to create multiplexed assays for detection of MI 7 and TBI biomarkers. In addition, we found that the assays for the cytokines IL-6 and IL-18 also 8 9 only specifically react with their own capture and detection antibody pair and do not cross-react with antibody pairs against other interleukin types (IL-6, IL-8, and IL-18)(Figure S11; 10

11 Supporting Information).

12




Figure 4: Specificity and cross-reactivity test for different biomarkers of Myocardial Infarction (MI) and
 Traumatic Brain Injury (TBI) done in 96 well plate. a) Specificity and cross-reactivity of NT-proBNP
 antigen against different non-specific capture and detection antibodies (anti-cTnITC, anti-BNP, anti-

1 GFAP, and anti-S-100b) along with specific detection with anti-NT-proBNP capture and detection 2 antibody at different concentrations of NT-proBNP. b) Specificity and cross-reactivity of BNP antigen 3 against different non-specific capture and detection antibodies along with specific detection with anti-4 BNP capture and detection antibody at different concentrations of BNP. c) Specificity and cross-reactivity 5 of GFAP antigen against different non-specific capture and detection antibodies along with specific 6 detection with GFAP capture and detection antibody at different concentrations of GFAP. d) Specificity 7 and cross-reactivity of S-100b antigen against different non-specific capture and detection antibodies 8 along with specific detection with S-100b capture and detection antibody at different concentrations of 9 GFAP.

10

11 2.4 Multiplexed Detection using Plasma and Whole Blood

12 The high sensitivity and selectivity of the antifouling nanocomposite combined with the use of 13 antibody pairs and corresponding target analytes that are free of any cross-reactivity made it

possible to create a highly multiplexed EC sensor for simultaneous detection of multiple

15 biomarkers both in plasma and whole blood. Different working electrodes in each EC sensor

16 were individually functionalized with one of four different capture antibodies directed against

17 cTnITC, S100, NT-proBNP, or anti-GFAP. Initially, we spiked plasma samples with different

18 concentrations of cTnITC (0.01-10 ng/mL) followed by all four detection antibodies and

19 observed a concentration-based signal only for cTnITC (Figure 5a), while minimal or no signals

20 were observed for the other biomarkers (S100, NT-proBNP, and GFAP) or in unspiked (blank)

21 plasma samples. We then spiked plasma samples with increasing concentrations of cTnITC

22 (0.01-10 ng/mL) and decreasing concentrations of GFAP (10-0.01 ng/mL) and observed specific

23 signal only for cTnITC and GFAP while no signal was observed for S100 and NT-proBNP along

24 with blank samples (Figure 5b). We then carried out similar multiplexed EC sensor assays in


25 human whole blood samples without any pre-treatment. In these studies, we were able to

specifically detect cTnITC and GFAP (Figure 5c) as well as S100 and GFAP (Figure 5d), and

27 develop calibration curves for each ligand simultaneously in multiplexed setting without

28 observing any cross-reactivity with the capture or detection antibodies even in unprocessed

29 whole blood.





3

4

5

6

7

Figure 5: Specificity and Multiplexed detection for different biomarkers of MI and TBI using antifouling nanocomposite coated EC Biosensors. a) Calibration curve for multiplex detection of cTnITC using plasma sample on the EC Biosensor with four different capture antibodies on each electrode (anti-cTnITC, anti-S-100b, anti-GFAP, and anti-NT-proBNP). b) Calibration curve for multiplex detection of increasing concentration of cTnITC (left y-axis) and decreasing concentration of GFAP (right y-axis) using plasma sample (c) and whole blood (d) on the EC Biosensor with four different capture antibodies on the context of the experimental detection detec


8 on each electrode. e) Calibration curve for multiplex detection of increasing concentration of s100 (left y-

9 axis) and decreasing concentration of GFAP (right y-axis) using whole blood on the EC Biosensor with

- 10 four different capture antibodies on each electrode. Error bars represent the s.d. of the mean; n = 3.
- 11
- 12
- 13 2.5 Detection of biomarkers in different complex biological fluids
- 14 For accurate disease diagnosis, a wide range of bodily fluids is employed in clinical settings,
- such as blood, serum, saliva, sputum, and sweat. However, the inherent biological and
- 16 physiochemical properties of these complex fluids often hinders clinical diagnosis. The most

common problem is that molecules present within these fluids can interact with the analyte or 1 with the sensor surface, which leads to the reduction of the signal.^[20] The sensitivity of EC 2 3 sensors also can be reduced due to limited access of redox molecules or analytes to the sensor 4 surface in these samples that can be highly viscous and rich in cells as well as molecules. Futhermore, most clinical biomarkers are present at very low concentrations (fM to pM range) in 5 these samples, and they can often cross-react with the large molecules, such as albumin and 6 7 immunoglobulins, which are present at much higher concentration (μ M to mM range).^[21] Biological samples are also unstable, and often environmental triggers have an impact in 8 antigen-antibody interaction, non-specific binding, and degradation of sample.^[21] Thus, the 9 detection of multiple biomarkers in clinical samples can provide different challenges due to the 10 complexities of the matrix.^[3] Given these observations, as the LOD is one of the critical 11 12 parameters in clinical bioassay, it must be measured in the complex fluid sample intended for use using the complete sample preparation sequence required to carry out the assay.^[20-22] 13 14 We have tackled these issues by developing a highly efficient antifouling coating, carrying out 15 16 rigorous screening of antibodies, and optimizing assay development. To validate the 17 nanocomposite's antifouling effect and show that our EC biosensor can perform the assay in 18 different complex biological fluids, we compared the efficiency of a single-step sandwich assay 19 for GFAP in buffer, plasma, and whole blood (Figure 6a). As expected, we observed a similar 20 calibration curve in the range of 0.01 to 10 ng/mL in all three samples (LOD of GFAP in buffer, plasma, and whole blood was 16, 7, and 2 pg/mL, respectively). The fact that the EC biosensor 21 22 with antifouling coating works similarly in unprocessed whole blood as well as plasma was also demonstrated by showing that the calibration curve for NF-L in whole blood and plasma closely 23

overlap each other, with LODs of 10 and 3 pg/mL, respectively (Figure 6b).



1

2

6 Detection of different concentration of NF-L (1, 0.05, and 0 ng/mL) at different % of hematocrit (20%-

7 70%). Line graph shows the mean current density for the assay of NF-L using plasma sample on EC

8 biosensor. Error bars represent the s.d. of the mean; n = 3.

9

10 2.6 Effect of hematocrit levels

11 Hematocrit levels (erythrocyte concentrations) in blood fluctuate between individuals and

various disease states, and they can impact the accuracy of biomarker detection in whole blood

- samples.^[23] We therefore measured the effect of different hematocrit levels (20%, 30%, 45%,
- 14 60%, and 70%) on the performance of the EC assay using a plasma sample as a control. When
- 15 we spiked these samples with two different concentrations of NF-L (0, 0.1, and 1 ng/mL) and

³ Figure 6: Matrix effect for detection of different biomarkers on EC Biosensors. a) Calibration curve of

⁴ *GFAP using buffer (black dot), plasma (orange), and whole blood (purple) on EC Biosensor. b)*

⁵ *Calibration curve of NF-L using plasma (black dot) and whole blood (blue) on EC Biosensor. c)*

blank, there were no significant difference in the signals observed between samples with
different hematocrits or in the plasma sample (Figure 6c).

3

4 **3. Discussion**

5 In this study, we described development methods and optimization strategies for creation 6 of multiplexed EC sensors that can be used to detect clinically relevant biomarkers in complex 7 biological fluids, such as unprocessed whole blood and plasma, with high sensitivity and 8 specificity as well as minimal cross reactivity. The optimization of individual components in 9 sandwich immunoassays combined with the high efficiency antifouling coating enabled highly sensitive detection with near-zero cross-reaction for selective biomarkers for MI, TBI, MS, and 10 11 TB when present in the clinically relevant range within plasma and blood samples. The ability of 12 these sensors to simultaneously detect multiple different biomarkers should allow for more accurate detection and evaluation of diseases with a limited quantity of clinical samples, in 13 14 addition to offering the possibility of early diagnosis at POC.

We achieved multiplexing of four different biomarkers in the same sensor by antibody 15 16 screening, assay parameter optimization, and carrying out cross-reactivity studies. Potential cross-reactivity was tested by replacing the actual antigen and antibodies (capture and detection) 17 with similar size proteins and non-specific antibodies. We consistently observed specific signals 18 19 for the real analytes with minimum readout when using non-specific molecules, which allowed 20 us to delineate the selectivity and also demonstrate superiority in terms of the accuracy of 21 detection. For instance, using NT-proBNP as cardiovascular disease protein biomarker, crossreactivity with non-specific protein biomarkers (BNP, cTnI, S100, and GFAP) was assessed 22 using similar sized antibodies and complex protein structures. When the capture antibodies 23 24 targeting the analytes were replaced with antibodies against other targets, the output signals were 25 consistently low or zero. In addition, the use of locally precipitating TMB allowed us to build 26 versatile multiplexed biosensors in close juxtaposition, each using a different antigen-antibody 27 pair, which do not cross-react.

EC sensors are not used often for clinical diagnosis or POC application largely because they are prone to electrode fouling when used with complex biological fluids. By integrating an antifouling nanocomposite coating, we were able to detect multiple disease biomarkers in

complex samples, such as human whole blood and plasma, and still obtain clinically relevant 1 2 LODs. Our studies on detection of the neurological disease biomarkers, GFAP and NF-L, also 3 demonstrated that hematocrit levels in blood had no significant effect on our EC biosensor with 4 antifouling coating. We expect that other biomarkers will show similar behaviors, but a detailed study should be carried out with each biomarker explored in the future. Moreover, the same 5 antifouling coating worked equally well when integrating different kinds of EC sensors, 6 including screen printed electrodes and transducer-like materials. Thus, this antifouling coating 7 8 is a key feature of our EC sensors that provides a significant advantage that is highly relevant for 9 clinical diagnostics as well as POC applications.

Finally, as a proof-of-concept, we leveraged our multiplexed EC sensor to develop a TB 10 diagnostic. Nearly 10 million people develop TB every year and this results in approximately 1.5 11 12 million deaths worldwide each year even though it is entirely curable with early diagnosis and an effective treatment plan.^[24] Current TB diagnostic tests are either difficult to access as they are 13 14 only available in hospital settings or they have low accuracy, reliability, yield delayed results, and require expertise and specialized facilities. In addition, sputum sample collection from 15 16 suspected TB patients is cumbersome, exacerbating the difficulty in making a timely diagnosis. An accurate POC device that could diagnose TB early and guide the use of medical treatment 17 18 would significantly improve the management of this disease in endemic areas, decreasing morbidity and slowing disease transmission.^[25] A combination of TB disease-specific biomarker 19 Antigen (Ag)85B (Ag85-B) and host response cytokines IL-6, IL-8, IL-18, and VEGF were 20 previously combined to configure a blood-based triage test for active pulmonary TB based on 21 22 analysis of an extensive cohort study.^[15] Importantly, the performance of this biomarker panel was validated by an independent blinded set of samples, and it meets the World Health 23 Organization's (WHO) mimimal target product profile (TPP) for a blood-based TB triage test. 24 25 Thus, we believe that this new approach for fabricating multiplexed EC sensors can be used to 26 develop POC diagnostics that could have near-term impact on healthcare world-wide.

In summary, in this study, we have addressed four significant challenges including, i) prevention of biofouling from the complex biological samples like blood, ii) choosing a coherent group of biomarkers that is highly specific to a disease condition, iii) developing sensitive assay without any cross-reaction, and iv) integrating the technology into a multiplexed EC sensor.

1 Combined, this approach enable rapid and cost-effective development of multiplexed biosensors

2 that provide highly sensitive and specific detection of various clinically relevant biomarkers for

3 complex diseases, as we demonstrated for TB, MI, and TBI. They also can be adapted to detect

4 any desired analyte if appropriate specific capture and detection molecules (e.g., antibodies,

5 aptamers, etc.) are available. Thus, these multiplexed EC sensor arrays could provide a new

6 approach to disease diagnosis as well as environmental monitoring in POC settings.

7

8 **4. Methods**

9 4.1 Fabrication of Electrochemical (EC) sensor

10 The EC sensor with gold electrodes which was purchased from Telic Company was custom 11 fabricated using a standard photolithography process. The chips were cleaned by sonicating in acetone 12 followed by isopropyl alcohol and cleaned with plasma cleaner for 8 min as described previously.^[8b] 13 Antifouling coating solution consisting of prGOx and BSA crosslinked with GA was drop-casted over the 14 chips at 85 °C for 45s.^[8a] The chips were then washed by dipping in PBS immediately at 400 rpm for 10 15 min.

16

17 4.2 Conjugation of Capture Antibodies

18 After drying the coated chips with a slide spinner (Millipore Sigma, no. 674 664), 400 mM EDC 19 (Thermo Fisher Scientific, no. 22 980) and 200 mM NHS (Sigma-Aldrich, no. 130 672) were dissolved in 20 0.05 M MES (2-(N-morpholino)ethanesulfonic acid) Buffer (pH 6.2) and deposited over the chips for 30 21 min at room temperature in dark. The chips were then quickly rinsed with Milli Q water and dried with 22 compressed air followed by spotting of optimized concentration of capture antibody on top of three 23 working electrodes and BSA (5 mg/mL) over the 4th electrode as a negative control using Xtend capillary microarray Pin (LabNEXT, no. 007-350). The chips spotted with capture antibody and BSA were stored 24 25 overnight at 4 °C in a humidity chamber followed by washing with PBS. The chips were then exposed to 1 M ethanolamine (Sigma-Aldrich, USA, no. E9508) in PBS to quench the unreacted glutaraldehyde 26 27 groups for 30 min and blocked with 10 µL of 2.5% BSA in PBS for 1 h.

28

29 4.3 Detection of Biomarkers in EC Sensor

30 Detection of different biomarkers on the EC biosensor was performed using the optimized

31 conditions. Three working electrodes were spotted with respective capture antibodies diluted in PBS

32 [anti-BNP (HyTest, no. 50E1cc), anti-NT-proBNP (Medix Biochemica, no. 100 521), anti-cTnI (Abcam,

no. ab243982), anti-cTnI-TC (Advanced ImmunoChemical, no. 2-TIC-rc) anti-GFAP (HyTest, no.

GFAP83cc), anti-S100b (HvTest, no. 8B10cc)], anti NF-L (Uman Diagnostics, no. 27016), anti-IL-6 1 2 (Abcam, ab246838), anti-IL-8 (Abcam, ab215402), anti-IL-18 (Abcam, ab218185), anti-VEGF (R&D 3 system DY493-05), and anti-Ag85-B (Abcam, ab36731). Antigens were then spiked into the plasma samples at different concentrations ranging from 1 pg/mL to 10,000 pg/mL and mixed with the optimized 4 concentration of biotin conjugated detection antibody in the ratio of 9:1. Different antigens used includes 5 [BNP-32 (Bachem, no. 4 095 916), NT-proBNP (Medix Biochemica, no. 610 090), cTnI (Medix 6 7 Biochemica, no. 610 102), cTnI-TC complex (HyTest, no. 8T62), GFAP (HyTest, no. 8G45), S100b 8 (HyTest, no. 8S9h), NF-L (Encor, no. PROT-r-NF-L), IL-6, IL-8, IL-18, VEGF, and Ag85-B, 9 respectively. 15 µL of the sample detection antibody mixture was then added to the EC biosensor and 10 incubated with agitation at 400 rpm for 30 min (single-step assay). For 2 step assay, 15 µL of the sample 11 antigen was incubated for 1 h followed by washing and the addition of 10 µL of detection antibody for 15 12 min. Conjugation of biotin to detection antibody was done using Biotin Conjugation Kit (Fast, Type A)-Lightning-Link (Abcam, USA, no. ab201795) using manufacturer's protocol except for anti-NF-L 13 14 detection antibody which was already linked with biotin when purchased. Detection antibodies used for 15 the assay include anti-BNP (HyTest, no. 24C5cc), anti-NT-proBNP (Medix Biochemica, no. 100712), 16 anti-cTnI (Abcam, no. ab243982), anticTnI-TC (Advanced ImmunoChemical, USA no. 2-TC), anti-17 GFAP (HyTest, no. GFAP81cc), anti-S-100b (HyTest, no. 6G1cc), anti NF-L (Uman Diagnostics, no. 18 27018), anti-IL-6, anti-IL-18, anti-VEGF, and anti-Ag85-B, respectively. After 30 min 19 incubation, the EC biosensors were washed with PBST (PBS with 0.05% Tween 20 (Sigma-Aldrich, no. 20 P9416)). 2-5 µg/mL of spHRP (Thermo Fisher Scientific, no. N200) diluted in 0.1% BSA in PBST was then added to each EC biosensor for 5 min followed by washing and addition of precipitating TMB, 21 22 Sigma-Aldrich, USA, no. T9455) membrane substrate for 2 min. The EC biosensors were finally washed 23 with PBST before taking the electrochemical measurements in PBST using a potentiostat by a CV with a 24 scan rate of 1 V/s between -0.5 and 0.5 V versus on-chip integrated gold quasi reference electrode. Linxens sensor was cleaned by dipping in 50 mg/mL sodium carbonate for 10s followed by rinsing in 25 water and dipping in 920 mM sulfuric acid for another 10s before final rinse with water. Gii-sens 26 27 electrode were directly used without cleaning. Linxens and Gii-sens electrode were characterized by measuring CV in PBS containing 5 mM [Fe(CN)₆]^{3-/4-} at 200 mV/s between -0.5 to 0.5V. All samples 28 29 were collected under the approval of the Institutional Review Board for Harvard Human Research 30 Protection Program (IRB21-0024).

31

32 4.4 Cross-reactivity

33 Specificity of Antigen and Antibody was performed in Nunc[™] MaxiSorp[™] ELISA plates
34 (BioLegend, no. 423501). For each biomarker four different concentrations were run with specific

1 antibody pairs to observe the signal for specific binding. To see if there is any non-specific binding of 2 antigen to capture antibody of other biomarkers, all the non-specific capture antibodies were coated to the 3 plates followed by the addition of high concentration analyte (10 ng/mL) and negative control (0 ng/ml) 4 and detection antibody for the analyte. To test non-specific binding between the antigen and detection antibody of other biomarkers, a specific capture antibody was coated to the plate and a high concentration 5 6 analyte (10 ng/mL) and negative control were added to the plate followed by all other non-specific 7 detection antibodies. All the assays were performed in buffer (1 % BSA in PBS). For instance, in case of 8 BNP specificity test, four concentrations of BNP (0, 0.1, 1, and 10 ng/mL) (black dots, Figure 4b) were 9 tested with specific antibody pair for BNP. For non-specific capture antibody-antigen binding test, four 10 different capture antibodies (anti-NT-pro BNP, anti-CTnI, anti-GFAP, and anti-S100) were coated at 1 11 µg/mL followed by the addition of either 10 ng/mL or 0 ng/mL of BNP. After washing anti-BNP 12 detection antibody was added followed by Streptavidin-HRP and TMB (ThermoScientific, no. 34022). Similarly, for the non-specific antigen-detection antibody binding test, BNP capture antibody followed by 13 14 0 or 10 ng/mL of BNP was added. After washing, non-specific biotinylated detection antibodies (anti-NT-15 proBNP, anti-cTnI, anti-GFAP, and anti-S100) were added followed by Streptavidin-HRP and TMB. 16 Likewise, specificity test for other biomarkers including NT-proBNP, GFAP, and S100 was done in 17 similar way with specific and non-specific antigen-antibody pairs. Similarly, for cTnI and cTnITC 18 specificity test was performed with both Abcam antibody pair (specific to cTnI) and Advanced 19 ImmunoChemical antibody pair (specific to cTnITC). Likewise, cross-reactivity test was also performed

- 20 for different biomarkers of TB including II-6, IL-8, and IL-18.
- 21

22 4.5 Multiplexed detection of Biomarkers in EC Platform

23 For the detection of cTnITC in multiplexed EC biosensor, four different capture antibodies (anti-24 cTnITC, anti-S100, anti-NT-proBNP, and anti-GFAP) were spotted on four different electrodes of the chip at 500 µg/mL. Increasing concentration of cTnITC (0, 0.01, 0.05, 0.1, 1, and 10 ng/mL) spiked in 25 plasma samples were mixed with optimum concentration of all four biotinylated detection antibodies and 26 27 added to the EC biosensor for 30 min. Chips were washed and spHRP was added for 5 min followed by 28 TMB for 2min before washing and reading the chips. In the next experiment for parallel detection of 29 cTnITC and GFAP, all capture antibodies were spotted as earlier. Increasing concentration of cTnITC and 30 decreasing concentration of GFAP (0.01 cTnITC + 10 GFAP; 0.05 cTnITC +1 GFAP; 0.1 cTnITC + 0.1 31 GFAP; 1 cTnITC + 0.05 GFAP; 10 cTnITC + 0.01 GFAP) spiked in plasma samples was mixed with all 32 four biotinylated detection antibody and incubated for 30 min. Likewise, simultaneous multiplexed 33 detection of cTnITC and GFAP was performed in unprocessed whole blood with increasing concentration 34 of cTnITC and decreasing concentration of GFAP (0.01 cTnITC + 10 GFAP; 0.05 cTnITC +1 GFAP; 0.1

- cTnITC + 0.1 GFAP; 1 cTnITC + 0.05 GFAP; 10 cTnITC + 0.01 GFAP). Similarly, simultaneous
 multiplexed detection of \$100 and GFAP in the whole blood sample was also performed.
- 3

4 **4.6 Matrix and hematocrit effects**

The effect of different types of matrices on the performance of EC biosensor was evaluated by 5 6 running the calibration curve of GFAP using buffer (2.5 % BSA in PBS), plasma, and whole blood 7 sample with the optimized conditions. The antifouling effect of different matrix components was further 8 evaluated by running a calibration curve of NF-L in plasma vs unprocessed whole blood. To study the 9 hematocrit effect, whole blood samples collected in Sodium heparin tube was used to separate plasma 10 from RBCs. Briefly, Heparinized tubes were centrifuged for 10 minutes at 1,500 x g using a refrigerated 11 centrifuge. Following centrifugation, plasma was immediately transferred into a clean polypropylene tube 12 using a pipette and kept over ice. Blood samples with different nominal hematocrit values in the range of 13 20 to 70% were then prepared by mixing different ratios of plasma and RBCs followed by gentle mixing. 14 EC assay of NF-L was immediately performed after the preparation of plasma and whole blood with 15 different hematocrit levels.

16

17 **4.7 Statistical Analysis**

ELISA reading is reported as absorbance (a.u.) of the mean of replicates and error bars represent the standard deviation (s.d.) of the mean; n = 2. For EC biosensor studies, peak heights were calculated using Nova 1.11 software. For data analysis peak height (μ A) was converted to current density (μ A/mm²) for further analysis by dividing the peak height by the surface area of the working electrode (0.1576 mm²). Error bars represent mean ± s.d. for all EC biosensor studies (sample sizes and statistical tests used are indicated in the Figure legends). All data were plotted, and statistical tests were performed using GraphPad Prism 8, and 4-Parameter Logistic (4PL) curve fitting was done for calibration curve analysis.

25

26 Supporting Information

Supporting Information is available from the Wiley Online Library or from the author.
Supporting Information includes optimization of coating time, TMB stability, Linxens and Gii-sens
characterization, two-step calibration curves, optimization studies, cross-reactivity studies, and calibration
curve.

1 Acknowledgments

2	We would like to acknowledge Linxens and Integrated Graphene for providing the electrodes for		
3	the study. This work was supported by the Wyss Institute for Biologically Inspired Engineering at		
4	Harvard University. MR was supported from Internal funding from bioengineering at UTD		
5			
6	Author contributions		
7	SS, MR, ND conceived the study under the guidance of RA, PJ, and DEI. MR under the guidance	e	
8	of RA and PJ contributed to TB-related work. Experiments were performed and validated by SS, MR, and		
9	ND. All authors contributed to discussion, manuscript preparation, and editing.		
10			
11	Conflict of Interests		
12	This technology has been licensed to Antisoma Therapeutics Inc. for infectious disease and		
13	cancer diagnostics and to StataDX Inc. for neurological and kidney disease diagnostics; P.J. and D.E.I.		
14	hold equity in StataDx and D.E.I. is a board member; S.S.T., N.D., P.J., and D.E.I are also listed as		
15	inventors on patents describing this technology. RA is listed as inventor on a patent for the TB		
16	biomarkers (IL-6, IL-8, IL-18 and VEGF). The remaining authors declare no competing interests.		
17			
18	REFERENCES		
19	[1] J. Yang, K. Wang, H. Xu, W. Yan, Q. Jin, D. Cui, <i>Talanta</i> 2019 , 202, 96.		
20 21	[2] X. Li, Y. Zhang, B. Xue, X. Kong, X. Liu, L. Tu, Y. Chang, H. Zhang, <i>Biosensors and Bioelectronics</i> 2017 , 92, 517.		
 22 23	 [3] Y. Rosenberg-Hasson, L. Hansmann, M. Liedtke, I. Herschmann, H. T. Maecker, <i>Immunologic research</i> 2014, 58, 224. 		
24	[4] a) A. Kaushik, M. A. Mujawar, Vol. 18, Multidisciplinary Digital Publishing Institute, 2018, 4303;		

- b) K. S. Prasad, X. Cao, N. Gao, Q. Jin, S. T. Sanjay, G. Henao-Pabon, X. Li, Sensors and Actuators *B: Chemical* 2020, 305, 127516; c) C. Dincer, R. Bruch, A. Kling, P. S. Dittrich, G. A. Urban, Trends *in biotechnology* 2017, 35, 728.
- S. S. Timilsina, P. Jolly, N. Durr, M. Yafia, D. E. Ingber, Accounts of Chemical Research 2021, 54,
 3529.
- a) N. Arroyo-Currás, P. Dauphin-Ducharme, K. Scida, J. L. Chávez, *Analytical Methods* 2020, 12,
 1288; b) S. Campuzano, M. Pedrero, M. Gamella, V. Serafín, P. Yáñez-Sedeño, J. M. Pingarrón, *Sensors* 2020, 20, 3376.
- U. Zupančič, P. Jolly, P. Estrela, D. Moschou, D. E. Ingber, *Advanced Functional Materials* 2021,
 31, 2010638.

1 2 3	[8]	a) S. S. Timilsina, N. Durr, M. Yafia, H. Sallum, P. Jolly, D. E. Ingber, <i>Advanced healthcare materials</i> 2021 , e2102244; b) J. Sabaté del Río, O. Y. Henry, P. Jolly, D. E. Ingber, <i>Nature nanotechnology</i> 2019 , 14, 1143.
4 5 6	[9]	a) S. T. Sanjay, M. Dou, J. Sun, X. Li, <i>Scientific reports</i> 2016 , 6, 1; b) M. Dou, S. T. Sanjay, D. C. Dominguez, S. Zhan, X. Li, <i>Chemical communications</i> 2017 , 53, 10886; c) X. Wei, W. Zhou, S. T. Sanjay, J. Zhang, Q. Jin, F. Xu, D. C. Dominguez, X. Li, <i>Analytical chemistry</i> 2018 , 90, 9888.
7 8	[10]	I. Taneja, G. L. Damhorst, C. Lopez - Espina, S. D. Zhao, R. Zhu, S. Khan, K. White, J. Kumar, A. Vincent, L. Yeh, <i>Clinical and translational science</i> 2021 , 14, 1578.
9	[11]	M. M. Ling, C. Ricks, P. Lea, Expert review of molecular diagnostics 2007, 7, 87.
10	[12]	N. Madaboosi, R. R. Soares, V. Chu, J. P. Conde, Analyst 2015, 140, 4423.
11	[13]	a) M. M. Redfield, R. J. Rodeheffer, S. J. Jacobsen, D. W. Mahoney, K. R. Bailey, J. C. Burnett,
12		Journal of the American College of Cardiology 2002, 40, 976; b) T. Mueller, M. Egger, E. Peer, E.
13		Jani, B. Dieplinger, <i>Clinica Chimica Acta</i> 2018 , 487, 66.
14	[14]	D. C. Malaspina, G. Longo, I. Szleifer, <i>PLoS One</i> 2017 , 12, e0185518.
15 16	[15]	R. Ahmad, L. Xie, M. Pyle, M. F. Suarez, T. Broger, D. Steinberg, S. M. Ame, M. G. Lucero, M. J. Szucs, M. MacMullan, <i>Science translational medicine</i> 2019 , 11, eaaw8287.
17 18	[16]	C. T. Turner, R. K. Gupta, E. Tsaliki, J. K. Roe, P. Mondal, G. R. Nyawo, Z. Palmer, R. F. Miller, B. W. Reeve, G. Theron, <i>The Lancet Respiratory Medicine</i> 2020 , 8, 407.
19	[17]	a) J. Dinulos, Habif's Clinical Dermatology. 7th ed. Philadelphia, PA: Elsevier 2021; b) N. I.
20		Rashwan, M. H. Hassan, Z. M. M. El-Deen, A. El-Abd Ahmed, Pediatrics & Neonatology 2019, 60,
21		149.
22	[18]	a) K. N. Varhaug, Ø. Torkildsen, KM. Myhr, C. A. Vedeler, <i>Frontiers in neurology</i> 2019 , 10, 338;
23		b) N. Siller, J. Kuhle, M. Muthuraman, C. Barro, T. Uphaus, S. Groppa, L. Kappos, F. Zipp, S.
24		Bittner, Multiple Sclerosis Journal 2019 , 25, 678.
25	[19]	J. Tate, G. Ward, The clinical biochemist reviews 2004, 25, 105.
26	[20]	M. L. Chiu, W. Lawi, S. T. Snyder, P. K. Wong, J. C. Liao, V. Gau, JALA: Journal of the Association
27		for Laboratory Automation 2010 , 15, 233.
28	[21]	M. A. Johansson, KE. Hellenäs, Analyst 2004, 129, 438.
29	[22]	J. Sun, Y. Liu, Micromachines 2018, 9, 142.
30	[23]	a) P. Denniff, N. Spooner, <i>Bioanalysis</i> 2010 , 2, 1385; b) G. N. Eick, P. Kowal, T. Barrett, E. A.
31		Thiele, J. J. Snodgrass, Biodemography and Social Biology 2017, 63, 116.
32	[24]	A. MacNeil, P. Glaziou, C. Sismanidis, A. Date, S. Maloney, K. Floyd, Morbidity and Mortality
33		Weekly Report 2020 , 69, 281.
34	[25]	K. Dheda, M. Ruhwald, G. Theron, J. Peter, W. C. Yam, Respirology 2013, 18, 217.
35		
36		
37		
38		
39		
40		
41		

TOC figure:

